Jms Co.,Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended September 30, 2017; Announces Consolidated Earnings Guidance for the Year Ending March 31, 2018; Declares Dividend for the Second Quarter Ended September 30, 2017, Payable on December 8, 2017; Provides Year-End Dividend Guidance for the Year Ending March 31, 2018
November 08, 2017
Share
JMS Co.,Ltd. reported unaudited consolidated earnings results for the second quarter ended September 30, 2017. For the second quarter, the company's net sales were ¥27,402 million against ¥27,526 million last year. Operating income was ¥156 million against ¥592 million last year. Ordinary income was ¥334 million against ¥699 million last year. Profit attributable to owners of parent was ¥210 million or ¥8.65 per share against ¥409 million or ¥16.82 per share last year. Net cash provided by operating activities was ¥2,399 million against ¥2,399 million last year. Purchase of property, plant and equipment was ¥3,689 million against ¥1,723 million last year. Purchase of intangible assets was ¥82 million against ¥45 million last year.
For the year ending March 31, 2018, the company expects net sales of ¥56,000 million, operating income of ¥700 million, ordinary income of ¥900 million, and profit attributable to owners of parent of ¥600 million or ¥24.62 per share against previous guidance of net sales of ¥57,000 million, operating income of ¥1,150 million, ordinary income of ¥1,200 million, and profit attributable to owners of parent of ¥700 million.
The company declared dividend of JPY 4.00 per share for the second quarter ended September 30, 2017 against JPY 4.00 per share for the same period a year ago, payable on December 8, 2017.
The company expects to pay a year-end dividend of JPY 8.00 per share for the year ending March 31, 2018 against JPY 4.00 per share for the same period a year ago.
JMS CO.,LTD. is a Japan-based company mainly engaged in the manufacture and sale of medical equipment and drugs. The Company operates through five geographical segments including Japan, Singapore, China, Philippines and Germany. The Company is engaged in the manufacture and sale of infusion and nutrition products, dialysis products, surgery products, blood and cell products and other products. The Companyâs main products include infusion & transfusion set, syringe pump, surgical gown, dialysis kit, peritoneal dialysate, microcatheter, blood bag, among others. The Company is also involved in the provision of maintenance service and other related services.
Jms Co.,Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter Ended September 30, 2017; Announces Consolidated Earnings Guidance for the Year Ending March 31, 2018; Declares Dividend for the Second Quarter Ended September 30, 2017, Payable on December 8, 2017; Provides Year-End Dividend Guidance for the Year Ending March 31, 2018